Total Return CAGR:-52.14%(TTM)
Over the latest trailing 12-month period, total return cagr is -52.14%. The comparable SPY value is +22.18%. Year-to-date total return is -47.62%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Total Return CAGR averages -19.71% over 3 years and -11.68% over 5 years. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
PODD Total Return CAGR Chart
Insulet Corp. (PODD)
PODD Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
PODD Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 1780.95 | 932.83 | -848.12 | -47.62% | -47.62% |
| 2025 | 1635.78 | 1780.95 | +145.18 | +8.88% | +8.88% |
| 2024 | 1359.52 | 1635.78 | +276.25 | +20.32% | +20.32% |
| 2023 | 1844.55 | 1359.52 | -485.03 | -26.30% | -26.30% |
| 2022 | 1667.11 | 1844.55 | +177.44 | +10.64% | +10.64% |
| 2021 | 1601.69 | 1667.11 | +65.41 | +4.08% | +4.08% |
| 2020 | 1072.68 | 1601.69 | +529.01 | +49.32% | +49.32% |
| 2019 | 496.99 | 1072.68 | +575.69 | +115.83% | +115.83% |
| 2018 | 432.33 | 496.99 | +64.66 | +14.96% | +14.96% |
| 2017 | 236.09 | 432.33 | +196.24 | +83.12% | +83.12% |
| 2016 | 236.90 | 236.09 | -0.81 | -0.34% | -0.34% |
| 2015 | 288.60 | 236.90 | -51.69 | -17.91% | -17.91% |
| 2014 | 232.46 | 288.60 | +56.14 | +24.15% | +24.15% |
| 2013 | 132.96 | 232.46 | +99.50 | +74.84% | +74.84% |
| 2012 | 117.98 | 132.96 | +14.97 | +12.69% | +12.69% |
| 2011 | 97.12 | 117.98 | +20.86 | +21.48% | +21.48% |
| 2010 | 89.47 | 97.12 | +7.64 | +8.54% | +8.54% |
| 2009 | 48.37 | 89.47 | +41.10 | +84.97% | +84.97% |
| 2008 | 147.12 | 48.37 | -98.75 | -67.12% | -67.12% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 933 | -31.1% | -52.6% |
| Q1 2026 | 1,353 | -25.2% | -18.5% |
| Q4 2025 | 1,808 | -11.7% | +8.6% |
| Q3 2025 | 2,049 | +4.1% | +36.8% |
| Q2 2025 | 1,969 | +18.6% | +55.7% |
| Q1 2025 | 1,660 | -0.3% | +60.0% |
| Q4 2024 | 1,665 | +11.2% | +21.1% |
| Q3 2024 | 1,498 | +18.4% | +50.0% |
| Q2 2024 | 1,264 | +21.9% | -30.0% |
| Q1 2024 | 1,037 | -24.6% | -46.8% |
| Q4 2023 | 1,375 | +37.8% | -25.6% |
| Q3 2023 | 998 | -44.8% | -30.9% |
| Q2 2023 | 1,807 | -7.4% | +26.6% |
| Q1 2023 | 1,950 | +5.5% | +19.4% |
| Q4 2022 | 1,849 | +28.0% | +10.9% |
| Q3 2022 | 1,445 | +1.3% | -17.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy